2015;373:2117 28. S4.2-10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and car- diovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644 57. S4.2-11. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311 22. S4.2-12. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347 57. S4.2-13. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and car- diovascular outcomes in patients with type 2 diabetes and cardio- vascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519 29. S4.2-14. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovas- cular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834 44. S4.2-15. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics 2018 update: a report from the American Heart Association. Circulation. 2018;137:e67 492. S4.2-16. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and car- diovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383 93. S4.2-17. Liu G, Li Y, Hu Y, et al. Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus. J Am Coll Cardiol. 2018;71:2867 76. S4.2-18. Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobil- ity in obese adults with type 2 diabetes. N Engl J Med. 2012;366: 1209 17. S4.2-19. Burger KNJ, Beulens JWJ, van der Schouw YT, et al. Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS ONE. 2012;7:e43127. S4.2-20. 